Redirecting to https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-for-treatment-of-patients-with-resectable-t%e2%89%a54-cm-or-n-nsclc-in-combination-with-chemotherapy-as-neoadjuvant-treatment-then-continued-as-a-single/...

Click here if your browser doesn't automatically take you to this page.